Durvalumab After Chemoradiotherapy for Patients With Unresectable Stage III NSCLC: The PACIFIC-R Study. Zhao B, Li H, Ma W. J Thorac Oncol 2023;18:e38-e39.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhao B, Li H, Ma W. Durvalumab After Chemoradiotherapy for Patients With Unresectable Stage III NSCLC: The PACIFIC-R Study. J Thorac Oncol 2023;18:e38-e39.
PMID: 36990576